Russia’s pharmaceutical company NovaMedica (a Rusnano portfolio company) has registered Relonova, a drug of its own development, used to relieve headaches during migraine attacks. This is the first rizatriptan-based drug fully localized in the Russian Federation, as the company’s press service told GxP News.
The drug will be produced at the facilities of NovaMedica Innotech Technology Center in Moscow. The drug will be available on prescription and only for adult patients.
Relonova is intended for emergency treatment of pain during migraine attacks. It can also be used in patients with a long history of migraine, when the effectiveness of other analgesics decreases.
NovaMedica’s press service stressed that Relonova has become the fourth drug that the company developed and registered over the past year. Previously, registration was granted for therapies for dementia and Alzheimer’s disease, insomnia, and severe pain.
